Arvenin I

Synonyms: 葫芦素B 2-O-BETA-D-葡萄糖苷
Arvenin I 是一种天然的葫芦素葡萄糖苷,能够在肿瘤竞争性微环境中激活 T 细胞,并通过共价修饰并超活化 MKK3,进而经由 p38MAPK 通路恢复耗竭 T 细胞的线粒体 (mitochondrial) 功能,对多种癌细胞具有广谱抗增殖作用,在小鼠模型中单独使用或与免疫检查点抑制剂联用时均能增强抗肿瘤功效,可用于结肠癌、乳腺癌、肺癌和卵巢癌等癌症的相关研究。
产品编号: MS-I18992 纯度: 89.41% CAS No.: 65247-27-0 分子式: C38H56O13 分子量: 720.84
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价

产品描述

Arvenin I 是一种天然的葫芦素葡萄糖苷,能够在肿瘤竞争性微环境中激活 T 细胞,并通过共价修饰并超活化 MKK3,进而经由 p38MAPK 通路恢复耗竭 T 细胞的线粒体 (mitochondrial) 功能,对多种癌细胞具有广谱抗增殖作用,在小鼠模型中单独使用或与免疫检查点抑制剂联用时均能增强抗肿瘤功效,可用于结肠癌、乳腺癌、肺癌和卵巢癌等癌症的相关研究。

生物实验数据

生物活性 Arvenin I is a natural cucurbitacin glucoside that activates T cells in the tumor-competitive microenvironment, restores mitochondrial function in exhausted T cells by covalently modifying and hyperactivating MKK3 via the p38MAPK pathway, exhibits broad-spectrum antiproliferative activity against multiple cancer cell lines, enhances antitumor efficacy both alone and in combination with immune checkpoint inhibitors in mouse models, and can be used for research on cancers such as colon cancer, breast cancer, lung cancer, and ovarian cancer.
体外研究
(In Vitro)

Arvenin I (0.5-4 μM,48 小时) 在无 PHA 和 PMA (MS-C34076) 刺激时,未在 Jurkat PD-1 细胞中检测到 IL-2 的诱导,且在 4 μM 浓度下对 Jurkat PD-1 细胞未表现出显著细胞毒性,表明其不能独立激活 T 细胞,而是增强 PHA/PMA 诱导的 T 细胞活化。
Arvenin I (0-30 μM,24-48 小时) 通过其迈克尔受体结构域与 AKT (Cys310) 和 MKK3 (Cys227) 的特定位点半胱氨酸形成共价键,从而激活 MKK3-p38MAPK 信号通路,导致 IL-2 产量增加。
Arvenin I (250 nM,2 小时) 通过 p38MAPK 通路增强原代 CD8+ T 细胞的线粒体生物能量学,表现为提高基础呼吸、最大呼吸及备用呼吸能力。
Arvenin I (1-100 μM,3 天) 对人类癌细胞系表现出广谱抗增殖活性,在 A-549、HT-29、OVCAR 和 MCF-7细胞中的 IC50 值分别为 17.0、49.4、14.7 和 42.8 μM。

Western Blot Analysis

Cell Line: HEK293 and Jurkat PD-1 cells
Concentration: 0, 3, 10, and 30 μM for HEK293 cells; 0, 2, and 4 μM for Jurkat PD-1 cells
Incubation Time: 24 h
Result: Caused slightly slower electrophoretic migration of the Western-blotted bands of Flag-AKT wt and Flag-MKK3 wt on SDS-PAGE gels at concentrations as low as 3 μM.
Failed to induce a band shift in mutants where each corresponding cysteine residue was substituted with a serine residue (Flag-AKT C310S and Flag-MKK3 C227S), even at a high concentration of 30 μM.
Markedly increased the phosphorylation of p38MAPK Thr180/Tyr182 in Jurkat hPD-1 cells either in the presence or absence of PHA and PMA.
Had no detectable effects on the phosphorylation of FOXO1 Ser256.
Increased the phosphorylation of MKK3 in Jurkat hPD-1 cells.

Cell Viability Assay

Cell Line: Jurkat PD-1 cells
Concentration: 0.5, 1, 2, and 4 μM
Incubation Time: 48 h
Result: Exhibited no significant cytotoxicity in Jurkat PD-1 cells at 4 μM.

ELISA Assay

Cell Line: Jurkat PD-1, Jurkat MKK3 wild-type and C227S cells
Concentration: 4 μM
Incubation Time: 48 h
Result: Its ability to restore IL-2 production (suppressed by MDA-MB-231 conditioned medium) was dose-dependently canceled by SB203580 (MS-T90664).
Potentiated the augmentation of IL-2 production resulting from the overexpression of wild-type MKK3.
体内研究
(In Vivo)

Arvenin I (6 mg/kg, i.p., 腹腔注射,从第 10 天至第 22 天每 3 天一次) 在免疫正常的 MC38 荷瘤小鼠中抑制肿瘤生长,但在 Rag2KO 小鼠中无效,证明其抗肿瘤功效完全依赖于适应性免疫系统。

Animal Model: WT C57BL/6N mice (6 weeks old) subcutaneously injected with MC38 colon cancer cells
Dosage: 6 mg/kg
Administration: i.p., every 3 days from day 10 to day 22
Result: Caused a 40% inhibition of tumor growth in comparison to the control group, comparable to the efficacy of the PD-L1 antibody (30 μg every 6 day from day 10 to day 22).
Produced approximately 70% inhibition of tumor growth with a combination with PD-L1 antibody.
Did not lead to significant reductions in body weight or differences in liver toxicity markers, including AST, ALT, and LDH.
Significantly enhanced mitochondrial respiration and upregulated proliferation markers (Ki67) in DLN CD8+ T cells in combination with the PD-L1 antibody.
Increased TNF-α levels but reduced IFN-γ levels in combination with the PD-L1 antibody.
Showed a trend toward decreasing the population of terminally exhausted CD8+ T cells (PD1+ Tim3+) and increasing the proportion of less exhausted CD8+ T cells in the combination group.
Animal Model: Rag2KO C57BL/6N mice (6 weeks old) subcutaneously injected with MC38 colon cancer cells
Dosage: 6 mg/kg
Administration: i.p., every 3 days from day 10 to day 22
Result: Failed to suppress tumors in immunodeficient mice, thereby demonstrating that its antitumor efficacy is depends on the adaptive immune system.
性状 固体
颜色 Off-white to light yellow

化学信息

分子量 720.84
分子式 C38H56O13
CAS No. 65247-27-0
别名 葫芦素B 2-O-BETA-D-葡萄糖苷

储存&溶解度

储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础